Profile
ZYBT TAK ZTS HLN TEVA VTRS
Company Name Zhengye Biotechnology Holding Limited Takeda Pharmaceutical Company Limited Zoetis Inc. Haleon plc Teva Pharmaceutical Industries Limited Viatris Inc.
Sector Healthcare Healthcare Healthcare Healthcare Healthcare Healthcare
Industry Drug Manufacturers - Specialty & Generic Drug Manufacturers - Specialty & Generic Drug Manufacturers - Specialty & Generic Drug Manufacturers - Specialty & Generic Drug Manufacturers - Specialty & Generic Drug Manufacturers - Specialty & Generic
Market Cap $39.83M $56.52B $56.15B $49.48B $39.78B $14.94B
Employees 0.28K 49.28K 13.80K 24.56K 37.00K 32.00K
CEO Songlin Song Christophe Weber Kristin C. Peck Brian James McNamara Richard D. Francis Scott Andrew Smith
Ratings
ZYBT TAK ZTS HLN TEVA VTRS
Quant Rating Score 1 3 3 4 3 2
Quant Rating Strong Sell Neutral Neutral Buy Neutral Sell
Trading
ZYBT TAK ZTS HLN TEVA VTRS
Last Close $2.185 $14.14 $118.8 $9.68 $24.59 $10.66
High 52 $14.03 $15.52 $178.71 $11.41 $25.83 $13.37
Low 52 $1.84 $12.89 $118.8 $8.73 $12.82 $7.26
Price vs. 52 Week High -84.43 % -8.89 % -33.52 % -15.16 % -4.8 % -20.27 %
Price vs. 52 Week Low 18.75 % 9.7 % 0 % 10.88 % 91.81 % 46.83 %
Total Return
ZYBT TAK ZTS HLN TEVA VTRS
1 Month Return -17.86 % 0.71 % -17.53 % 2.11 % 27.34 % 4.82 %
3 Month Return -72.13 % -6.73 % -21.96 % -0.05 % 36.16 % 0.28 %
6 Month Return -72.13 % 0.21 % -27.13 % -10.37 % 45.16 % 20.59 %
9 Month Return -52.81 % 1.73 % -24.08 % -3.1 % 48.4 % -1.84 %
YTD Return 0 % 6.8 % -27.09 % 1.47 % 11.57 % -14.38 %
1 Year Return 0 % 3.82 % -32.33 % 2.11 % 46.28 % -18.31 %
3 Year Return 0 % 0 % 0 % 0 % 0 % 0 %
5 Year Return 0 % 0 % 0 % 0 % 0 % 0 %
Dividends
ZYBT TAK ZTS HLN TEVA VTRS
Dividend Yield Percentage (TTM) - 3.6 % 1.59 % 1.41 % - 3.7 %
Dividend Paid and Capex Coverage Ration (TTM) 0.94 % 2.23 % 1.89 % 2.01 % 4 % 2.09 %
Dividend Per Share (TTM) - 198 % 2.03 % 0.06 % - 0.48 %
Payout Ratio (TTM) 141.66 % 277.04 % 32.55 % 27.27 % - -15.34 %
Growth
ZYBT TAK ZTS HLN TEVA VTRS
Asset Growth -1.33 % -0.34 % 0.76 % 3.61 % -12.97 %
Gross Profit Growth -29.69 % 9.63 % -0.19 % 10.86 % -12.66 %
Revenue Growth -11.95 % 8.33 % -0.61 % 4.32 % -4.46 %
Revenue 3 Year - 24.31 % 19.01 % 11.71 % -16.52 %
Revenue 5 Year - 55.65 % 33.95 % -1.27 % -39.86 %
Revenue 10 Year - 113.39 % 33.95 % -34.65 % -36.45 %
EBIT Growth -61.74 % 5.67 % 13.52 % -9.52 % -109.43 %
Net Income Growth -64.04 % 6.06 % 37.46 % 185.97 % -1259.41 %
Net Income 3 Yeari Growth Per Share - 27.46 % 4.91 % 155.65 % 49.38 %
Net Income 5 Yeari Growth Per Share - 74.46 % 122.63 % 133.65 % -1871.56 %
Net Income 10 Yeari Growth Per Share - 370.4 % 122.63 % -33.98 % -122.71 %
Operating Income Growth -63.46 % 10.52 % 10.52 % 1131.35 % -98.68 %
Operating Cash Flow Growth (CFG) -14.81 % 25.5 % 9.57 % -35.33 % -17.74 %
Operating 3 Year CFG - 39.36 % 71.6 % 0.19 % -22.68 %
Operating 5 Year CFG - 73.18 % 196.04 % 29.24 % -40.08 %
Operating 10 Year CFG - 420.39 % 196.04 % -77.86 % -24.47 %
EPS Growth - 7.68 % 33.33 % 184.83 % -1262.28 %
EPS Diluted Growth - 7.89 % 33.33 % 182.76 % -1269.98 %
Book Value Per Share - -2.96 % -1.63 % 36.19 % -8.42 %
Share Holder 3 Year Equity Growth Per Share - 9.65 % -37.97 % -2.08 % -7.88 %
Share Holder 5 Year Equity Growth Per Share - 85.42 % -40.16 % -24.81 % -26.41 %
Share Holder 10 Year Equity Growth Per Share - 301.38 % -40.16 % -80.23 % 90.51 %
Dividend Per Share Growth - 15.33 % 49.01 % - 0.45 %
Dividend 3 Year Growth Per Share - 73.18 % -49.79 % - 45.93 %
Dividend 5 Year Growth Per Share - 163.51 % -49.97 % - -
Dividend 10 Year Growth Per Share - 493.89 % -49.97 % -100 % -
Debt Growth -3.8 % -0.16 % 6.83 % -3.86 % -22.13 %
Free Cash Flow Growth -63.72 % 41.76 % 16.27 % -43.99 % -14.98 %
Updated On 31 Dec 2024 31 Dec 2024 31 Dec 2024 31 Dec 2025 31 Dec 2024
Profitability
ZYBT TAK ZTS HLN TEVA VTRS
Gross Profit Margin TTM 48.99 % 59.49 % 70.63 % 61.81 % 51.76 % 36.07 %
Return on Assets TTM 2.29 % 0.73 % 17.49 % 4.78 % 3.48 % -9.73 %
Return on Equity TTM 4.06 % 1.58 % 53.56 % 9.4 % 20.09 % -22.69 %
Return on Capital Employed TTM 4.6 % 3.59 % 26.48 % 8.34 % 11.54 % -8.43 %
Net Income Per EBT TTM 78.58 % 54.99 % 79.59 % 76.52 % 114.62 % 95.92 %
EBT Per Ebit TTM 87.56 % 44.75 % 94.2 % 88.09 % 39.3 % 149.32 %
EBIT Per Revenue TTM 8.82 % 10.28 % 37.63 % 20.49 % 18.15 % -18.25 %
Cash Flow To Debt Ratio TTM 47.49 % 23.13 % 40.09 % 12.02 % 11.62 % 13.47 %
Receivables Turnover TTM 2.11 5.89 6.1 5.14 4.68 3.94
Payables Turnover TTM 2.21 3.87 6.73 1.18 3.31 6.81
Inventory Turnover TTM 1.63 1.29 1.12 3.72 2.63 2.2
Fixed Asset Turnover TTM 73.03 % 214.23 % 241.44 % 589.57 % 392.13 % 488.38 %
Asset Turnover TTM 37.78 % 28.97 % 61.99 % 34.62 % 42.58 % 37.25 %
Operating Cash Flow Per Share TTM - 710.55 6.58 0.11 1.76 1.7
Free Cash Flow Per Share TTM - 589.53 5.06 0.1 1.32 1.37
Cash Per Share TTM - 48236.45 % 470.54 % 7.46 % 309.55 % 99.36 %
Operating Cash Flow Sales Ratio TTM 22.03 % 25.14 % 31.03 % 9.32 % 11.64 % 14.04 %
Free Cash Flow Operating Cash Flow Ratio TTM 32.34 % 82.97 % 76.82 % 90.65 % 74.99 % 80.65 %
Cash Flow Coverage Ratios TTM 47.49 % 23.13 % 40.09 % 12.02 % 11.62 % 13.47 %
Price To Free Cash Flows Ratio TTM 20.82 9.34 25.07 38.08 25.95 9.34
Price To Operating Cash Flows Ratio TTM - 7.75 19.35 35.1 19.5 7.62
Price Cash Flow Ratio TTM - 7.75 19.35 35.1 19.5 7.62
Income Statement (TTM)
ZYBT TAK ZTS HLN TEVA VTRS
Revenue $0.19B $4581.55B $9.26B $11.23B $17.26B $14.74B
Gross Profit $0.09B $3001.33B $6.4B $6.95B $8.94B $5.62B
Gross Profit Ratio 48.99% 65.51% 69.1% 61.85% 51.79% 38.15%
EBITDA $0.04B $1210.51B $3.87B $2.51B $3.14B $2.82B
Net Income $0.01B $107.93B $2.49B $1.44B $1.41B $-0.63B
EPS Diluted - 33.62 5.47 0.32 1.2 -0.53
Balance Sheet (MRQ)
ZYBT TAK ZTS HLN TEVA VTRS
Long Term Debt $0B $3966.33B $5.39B $8.62B $15.56B $14.22B
Total Liabilities $0.14B $7312.37B $9.47B $18.09B $32.83B $22.87B
Total Equity $0.35B $6935.98B $4.77B $16.22B $7.91B $18.64B
Total Investments $0B $382.4B $0.03B $0.14B $0B $1.7B
Total Debt $0.09B $4515.27B $6.74B $10.1B $17.38B $14.31B
Total Assets $0.49B $14248.34B $14.24B $34.32B $40.75B $41.5B
Cash Flow Statement (TTM)
ZYBT TAK ZTS HLN TEVA VTRS
Net Income $0.01B $107.93B $2.5B $1.44B $1.42B $-0.63B
Inventory $-0.01B $-34.97B $-0.04B $0.22B $0.15B $-0.72B
Dividends Paid $-0.02B $-302.5B $-0.79B $-0.57B $0B $-0.57B
Operating Cash Flow $0.04B $1057.18B $2.95B $2.3B $1.65B $2.3B
Capital Expenditure $-0.03B $-200.8B $-0.66B $-0.25B $-0.5B $-0.33B
Related Stocks
Ticker Name Price
ACB Aurora Cannabis Inc. 3.58
ACOR Acorda Therapeutics, Inc. 0.661
ACRX AcelRx Pharmaceuticals, Inc. 0.86
ADMP Adamis Pharmaceuticals Corporation 0.775
ADMS Adamas Pharmaceuticals, Inc. 8.22
AERI Aerie Pharmaceuticals, Inc. 15.25
AGRX Agile Therapeutics, Inc. 1.51
AKAN Akanda Corp. 1.04
ALIM Alimera Sciences, Inc. 5.54
ALVO Alvotech 5.21
ALVOW Alvotech 0.4508
AMPH Amphastar Pharmaceuticals, Inc. 28.57
AMRX Amneal Pharmaceuticals, Inc. 14.765
AMYT Amryt Pharma plc 14.7
ANIP ANI Pharmaceuticals, Inc. 79.785
APUS Apimeds Pharmaceuticals US, Inc 1.55
AQST Aquestive Therapeutics, Inc. 3.865
ASRT Assertio Holdings, Inc. 11.635
ATNX Athenex, Inc. 0.2031
AVDL Avadel Pharmaceuticals plc 21.64
ETFs With Exposure to ZYBT
Ticker ETF Name Weight Percentage Price
PGJ Invesco Golden Dragon China ETF 0.02232 30.16
Unlock